234 related articles for article (PubMed ID: 32315234)
41. [Not Available].
Mas L; Perrier A; Coulet F; Bachet JB
Bull Cancer; 2022 Nov; 109(11S):11S28-11S34. PubMed ID: 36535760
[TBL] [Abstract][Full Text] [Related]
42. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma.
Saborowski A; Vogel A; Segatto O
Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108
[TBL] [Abstract][Full Text] [Related]
43. Raw Fish Consuming Behavior Related to Liver Fluke Infection among Populations at Risk of Cholangiocarcinoma in Nakhon Ratchasima Province, Thailand.
Chavengkun W; Kompor P; Norkaew J; Kujapun J; Pothipim M; Ponphimai S; Kaewpitoon SJ; Padchasuwan N; Kaewpitoon N
Asian Pac J Cancer Prev; 2016; 17(6):2761-5. PubMed ID: 27356687
[TBL] [Abstract][Full Text] [Related]
44. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma.
Li F; Peiris MN; Donoghue DJ
Cytokine Growth Factor Rev; 2020 Apr; 52():56-67. PubMed ID: 31899106
[TBL] [Abstract][Full Text] [Related]
45. Liver fluke granulin promotes extracellular vesicle-mediated crosstalk and cellular microenvironment conducive to cholangiocarcinoma.
Arunsan P; Chaidee A; Cochran CJ; Mann VH; Tanno T; Kumkhaek C; Smout MJ; Karinshak SE; Rodpai R; Sotillo J; Loukas A; Laha T; Brindley PJ; Ittiprasert W
Neoplasia; 2020 May; 22(5):203-216. PubMed ID: 32244128
[TBL] [Abstract][Full Text] [Related]
46. Chimeric transcripts observed in non-canonical FGFR2 fusions with partner genes' breakpoint located in intergenic region in intrahepatic cholangiocarcinoma.
Yin L; Han Z; Feng M; Wang J; Xie Z; Yu W; Fu X; Shen N; Wang X; Duan A; Zhang Y; Ma J
Cancer Genet; 2022 Aug; 266-267():39-43. PubMed ID: 35749865
[TBL] [Abstract][Full Text] [Related]
47. Behavior-related risk factors for opisthorchiasis-associated cholangiocarcinoma among rural people living along the mekong river in five greater mekong subregion countries.
Songserm N; Charoenbut P; Bureelerd O; Pintakham K; Woradet S; Vanhnivongkham P; Cua LN; Uyen NTT; Cuu NC; Sripa B
Acta Trop; 2020 Jan; 201():105221. PubMed ID: 31654901
[TBL] [Abstract][Full Text] [Related]
48. Genomic profiling, prognosis, and potential interventional targets in young and old patients with cholangiocarcinoma.
Wang J; Shi Y; Chen J; Liu J; Zhao X; Pang J; Sun X; Tian Y; Ou Q; Xia F; Chen Y
Cancer Biol Ther; 2023 Dec; 24(1):2223375. PubMed ID: 37337460
[TBL] [Abstract][Full Text] [Related]
49. Changing patterns of prevalence in Opisthorchis viverrini sensu lato infection in children and adolescents in northeast Thailand.
Khuntikeo N; Sithithaworn P; Loilom W; Namwat N; Yongvanit P; Thinkhamrop B; Kiatsopit N; Andrews RH; Petney TN
Acta Trop; 2016 Dec; 164():469-472. PubMed ID: 27794488
[TBL] [Abstract][Full Text] [Related]
50. Serum antibody response to Opisthorchis viverrini antigen as a marker for opisthorchiasis-associated cholangiocarcinoma.
Akai PS; Pungpak S; Chaicumpa W; Viroj K; Bunnag D; Befus AD
Trans R Soc Trop Med Hyg; 1994; 88(4):471-4. PubMed ID: 7570848
[TBL] [Abstract][Full Text] [Related]
51. Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis.
Chusorn P; Namwat N; Loilome W; Techasen A; Pairojkul C; Khuntikeo N; Dechakhamphu A; Talabnin C; Chan-On W; Ong CK; Teh BT; Yongvanit P
Tumour Biol; 2013 Jun; 34(3):1579-88. PubMed ID: 23417858
[TBL] [Abstract][Full Text] [Related]
52. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ; Zhu AX
Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
[TBL] [Abstract][Full Text] [Related]
53. Spatial analysis of hepatobiliary abnormalities in a population at high-risk of cholangiocarcinoma in Thailand.
Thinkhamrop K; Suwannatrai AT; Chamadol N; Khuntikeo N; Thinkhamrop B; Sarakarn P; Gray DJ; Wangdi K; Clements ACA; Kelly M
Sci Rep; 2020 Oct; 10(1):16855. PubMed ID: 33033306
[TBL] [Abstract][Full Text] [Related]
54. Factors Associated with Periductal Fibrosis Diagnosed by Ultrasonography Screening among a High Risk Population for Cholangiocarcinoma in Northeast Thailand.
Intajarurnsan S; Khuntikeo N; Chamadol N; Thinkhamrop B; Promthet S
Asian Pac J Cancer Prev; 2016; 17(8):4131-6. PubMed ID: 27644673
[TBL] [Abstract][Full Text] [Related]
55. Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, Northeast Thailand.
Sriamporn S; Pisani P; Pipitgool V; Suwanrungruang K; Kamsa-ard S; Parkin DM
Trop Med Int Health; 2004 May; 9(5):588-94. PubMed ID: 15117303
[TBL] [Abstract][Full Text] [Related]
56. Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.
Ang C
J Gastroenterol Hepatol; 2015 Jul; 30(7):1116-22. PubMed ID: 25678238
[TBL] [Abstract][Full Text] [Related]
57. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
King G; Javle M
Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
[TBL] [Abstract][Full Text] [Related]
58. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
[TBL] [Abstract][Full Text] [Related]
59. Altered gene expression in Opisthorchis viverrini-associated cholangiocarcinoma in hamster model.
Loilome W; Yongvanit P; Wongkham C; Tepsiri N; Sripa B; Sithithaworn P; Hanai S; Miwa M
Mol Carcinog; 2006 May; 45(5):279-87. PubMed ID: 16550611
[TBL] [Abstract][Full Text] [Related]
60. Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations.
Murugesan K; Necchi A; Burn TC; Gjoerup O; Greenstein R; Krook M; López JA; Montesion M; Nimeiri H; Parikh AR; Roychowdhury S; Schwemmers S; Silverman IM; Vogel A
ESMO Open; 2022 Dec; 7(6):100641. PubMed ID: 36462464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
